Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Shots: Shots:
- Teva and Celltrion launch Truxima (rituximab-abbs) to treat RA in combination with MTX in patients with mod.to sev. active RA who have an inadequate response to one or more TNF antagonist therapies and to treat GPA and MPA in combination with glucocorticoids
- Truxima has received CMS pass-through status in the hospital outpatient setting and is expected to be available at a WAC of $845.55/ 100mg and $4-227.75/ 500mg vial
- In Oct’2016- the two companies entered into an exclusive partnership- under which TEVA got commercializing right in the US and Canada. In May’2019- the US FDA approved Truxima for all approved indication of the reference product- Rituxan
Click here to read full press release/ article | Ref: PRNewswire | Image: Celltrion
Related News: Teva and Celltrion Reports the Availability of Truxima (biosimilar- Rituxan) in the US
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
